Comparative Pharmacology
Head-to-head clinical analysis: VANTRELA ER versus WELLBUTRIN XL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VANTRELA ER versus WELLBUTRIN XL.
VANTRELA ER vs WELLBUTRIN XL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norepinephrine reuptake inhibitor and alpha-2 adrenergic receptor agonist; increases norepinephrine and serotonin availability in the prefrontal cortex.
Bupropion is a dopamine and norepinephrine reuptake inhibitor; its mechanism in smoking cessation is unknown.
VANTRELA ER (cialoxine sodium) 250 mg orally once daily with evening meal; maximum dose 500 mg per day.
150 mg orally once daily; may increase to 300 mg once daily after 4 days, with maximum 300 mg/day.
None Documented
None Documented
Approximately 24 hours (range 20-30 hours) allowing once-daily dosing; steady state reached in 5-7 days.
21 ± 9 hours (terminal half-life of bupropion); clinical context: steady-state reached in 5-6 days.
Primarily renal (70-80% as unchanged drug) with 10-15% biliary/fecal elimination.
Renal (87% as metabolites, 0.5% as parent drug) and fecal (10%).
Category C
Category C
NDRI Antidepressant
NDRI Antidepressant